limertinib,1934259-00-3

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

ASK120067

CAS No. : 1934259-00-3

MCE 国际站：ASK120067

产品活性：ASK120067 是一种有效的口服活性 EGFR^T790M 抑制剂 (IC₅₀:0.3 nM)，对 EGFR^WT(IC₅₀:6.0 nM) 具有选择性。ASK120067 是用于非小细胞肺癌 (NSCLC) 研究的第三代 EGFR-TKI。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK

作用靶点：EGFR

In Vitro: In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC₅₀ values of 0.3 nM and 0.5 nM, respectively, as well as the EGFR^exon19del sensitizing mutant (IC₅₀= 0.5 nM). The ₅₀ of ASK120067 against wild-type EGFR (EGFR^WT) is 6 nM.
ASK120067 selectively inhibits the growth of EGFR-mutant cell lines and exhibits potent antiproliferative activity in the mutant EGFR NSCLC cells, with IC₅₀ values of 12 nM, 6 nM and 2 nM against NCI-H1975 (T790M mutation), PC-9, and HCC827 cells (sensitizing mutations), respectively. However, it shows moderate or weak anti-growth activities in A431, LoVo and A549 cells (EGFR^WT), with IC₅₀ values ranging from 338 nM to 1541 nM.
ASK120067 (0.1-100 nM) inhibits the phosphorylation of EGFR at Tyrosine residue 1068 and its downstream signaling proteins AKT and ERK in NCI-H1975 cells (EGFR^L858R/T790M) even at low dosage (0.1-1 nM). Additionally, ASK120067 inhibits p-EGFR and p-Akt and p-erk in EGFR WT A431 cell until the concentration reaches 10 to 100 nM.

In Vivo: ASK120067 (oral gavage; 5-20 mg/kg; once daily; 21 days) results in significantly regressed tumor growth, with a tumor growth inhibition (TGI) rate of 85.7%, and administration of 10 mg/kg ASK120067 causes dramatic tumor shrinkage with a TGI rate of 99.3%, exhibiting a similar potency with Osimertinib.

相关产品：Gefitinib  |  Trastuzumab  |  Erlotinib  |  Cetuximab  |  AG490  |  Genistein  |  AG-1478  |  Pertuzumab  |  BI-4020  |  NSC 228155  |  Pelitinib  |  Mubritinib  |  TX1-85-1  |  Butein  |  Canertinib  |  PD168393  |  Daphnetin  |  AEE788  |  EGFR-IN-7  |  PD153035  |  Chrysophanol  |  Tyrphostin 23  |  BMS-599626 Hydrochloride  |  Lavendustin A  |  Trastuzumab emtansine  |  AV-412  |  Falnidamol

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。